| P50 | author | Daniele Santi | Q55979669 |
| | Carlo Alviggi | Q56959712 |
| P2093 | author name string | Manuela Simoni | |
| | Livio Casarini | |
| P2860 | cites work | Recombinant human follicle-stimulating hormone produces more oocytes with a lower total dose per cycle in assisted reproductive technologies compared with highly purified human menopausal gonadotrophin: a meta-analysis | Q21245540 |
| | Gonadotrophin-releasing hormone antagonists for assisted reproductive technology | Q24185849 |
| | Comparison of different stimulation protocols used in in vitro fertilization: a review | Q26799866 |
| | Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice | Q26829747 |
| | Assessing the quality of reports of randomized clinical trials: is blinding necessary? | Q27860973 |
| | The lutropin/choriogonadotropin receptor, a 2002 perspective | Q28214215 |
| | The Lutropin/Choriogonadotropin Receptor, A 2002 Perspective | Q29030892 |
| | A randomized clinical trial to determine optimal infertility treatment in older couples: the Forty and Over Treatment Trial (FORT-T). | Q33932756 |
| | LH and hCG action on the same receptor results in quantitatively and qualitatively different intracellular signalling | Q34447333 |
| | A review of luteinising hormone and human chorionic gonadotropin when used in assisted reproductive technology | Q34875744 |
| | Comparison of recombinant human luteinising hormone (r-hLH) and human menopausal gonadotropin (hMG) in assisted reproductive technology | Q35124852 |
| | GnRH agonist versus GnRH antagonist in ovarian stimulation: the influence of body mass index on in vitro fertilization outcome | Q80507876 |
| | Why is the clinical acceptance of gonadotropin-releasing hormone antagonist cotreatment during ovarian hyperstimulation for in vitro fertilization so slow? | Q81838930 |
| | Low-dose human chorionic gonadotropin may improve in vitro fertilization cycle outcomes in patients with low luteinizing hormone levels after gonadotropin-releasing hormone antagonist administration | Q84757841 |
| | Hormonal, functional and genetic biomarkers in controlled ovarian stimulation: tools for matching patients and protocols. | Q35822351 |
| | Differential response to sustained stimulation by hCG & LH on goat ovarian granulosa cells | Q35838695 |
| | Differential effects of estrogen and progesterone on development of primate secondary follicles in a steroid-depleted milieu in vitro. | Q35865970 |
| | Differences in Signal Activation by LH and hCG are Mediated by the LH/CG Receptor's Extracellular Hinge Region | Q36098101 |
| | LH in the follicular phase: neither too high nor too low. | Q36494664 |
| | GnRH analogues in the prevention of ovarian hyperstimulation syndrome | Q36957480 |
| | Endometrial morphology and modulation of hormone receptors during ovarian stimulation for assisted reproductive technology cycles | Q37160432 |
| | Costs of achieving live birth from assisted reproductive technology: a comparison of sequential single and double embryo transfer approaches | Q37444447 |
| | GnRH agonist versus GnRH antagonist in ovarian stimulation: an ongoing debate | Q38062967 |
| | Cryopreservation of human embryos and its contribution to in vitro fertilization success rates | Q38217050 |
| | Ovarian stimulation in ART - Unwinding pressing issues | Q38350818 |
| | Efficacy and safety of follitropin alfa/lutropin alfa in ART: a randomized controlled trial in poor ovarian responders | Q38381555 |
| | A pilot study of the use of low dose human menopausal gonadotropin in ovulation induction | Q38520109 |
| | Trends in 'poor responder' research: lessons learned from RCTs in assisted conception | Q38722378 |
| | β-arrestins regulate gonadotropin receptor-mediated cell proliferation and apoptosis by controlling different FSHR or LHCGR intracellular signaling in the hGL5 cell line | Q38753034 |
| | Interactions between androgens, FSH, anti-Müllerian hormone and estradiol during folliculogenesis in the human normal and polycystic ovary. | Q38938581 |
| | Cumulative live birth rates after one ART cycle including all subsequent frozen-thaw cycles in 1050 women: secondary outcome of an RCT comparing GnRH-antagonist and GnRH-agonist protocols | Q38994475 |
| | Conventional ovarian stimulation and single embryo transfer for IVF/ICSI. How many oocytes do we need to maximize cumulative live birth rates after utilization of all fresh and frozen embryos? | Q40151006 |
| | Lyophilised hMG versus rFSH in women with unexplained infertility undergoing a controlled ovarian stimulation with intrauterine insemination: a prospective, randomised study. | Q43154108 |
| | Modulation of folliculogenesis and steroidogenesis in women by graded menotrophin administration | Q44085087 |
| | Recombinant human LH supplementation during GnRH antagonist administration in IVF/ICSI cycles: a prospective randomized study | Q44932557 |
| | Advantages of recombinant follicle-stimulating hormone over human menopausal gonadotropin for ovarian stimulation in intrauterine insemination: a randomized clinical trial in unexplained infertility. | Q45127841 |
| | A randomized clinical trial to evaluate optimal treatment for unexplained infertility: the fast track and standard treatment (FASTT) trial. | Q45967067 |
| | Differences between lutropin-mediated and choriogonadotropin-mediated receptor activation | Q46725788 |
| | Absence of exon 10 of the human luteinizing hormone (LH) receptor impairs LH, but not human chorionic gonadotropin action | Q47937885 |
| | What is the optimum maximal gonadotropin dosage used in microdose flare-up cycles in poor responders? | Q48003610 |
| | IVF stimulation: protocols for poor responders | Q48603228 |
| | Association between the number of eggs and live birth in IVF treatment: an analysis of 400 135 treatment cycles | Q48673616 |
| | Effectiveness of highly purified human menopausal gonadotropin vs. recombinant follicle-stimulating hormone in first-cycle in vitro fertilization-intracytoplasmic sperm injection patients | Q48786073 |
| | Highly purified hMG versus recombinant FSH plus recombinant LH in intrauterine insemination cycles in women ≥35 years: a RCT. | Q50612787 |
| | Exogenous luteinizing hormone in controlled ovarian hyperstimulation for assisted reproduction techniques. | Q50668333 |
| | A prospective randomized noninferiority study comparing recombinant FSH and highly purified menotropin in intrauterine insemination cycles in couples with unexplained infertility and/or mild-moderate male factor. | Q51655479 |
| | Best practices of ASRM and ESHRE: a journey through reproductive medicine | Q56979817 |
| | Follicle-stimulating hormone potentiates the steroidogenic activity of chorionic gonadotropin and the anti-apoptotic activity of luteinizing hormone in human granulosa-lutein cells in vitro | Q61855531 |
| | Induction of follicular growth, ovulation and luteinization in the human ovary | Q66846655 |
| | Differential Binding Affinities of Rat Testis Luteinizing Hormone (LH) Receptors for Human Chorionic Gonadotropin, Human LH, and Ovine LH | Q72886625 |
| | Crosstalk Among Multiple Signaling Pathways Controlling Ovarian Cell Death | Q78168522 |
| P921 | main subject | meta-analysis | Q815382 |
| P304 | page(s) | 114 | |
| P577 | publication date | 2017-06-01 | |
| P1433 | published in | Frontiers in Endocrinology | Q27723680 |
| P1476 | title | Efficacy of Follicle-Stimulating Hormone (FSH) Alone, FSH + Luteinizing Hormone, Human Menopausal Gonadotropin or FSH + Human Chorionic Gonadotropin on Assisted Reproductive Technology Outcomes in the "Personalized" Medicine Era: A Meta-analysis | |
| P478 | volume | 8 | |